Novavax Gross Profit vs Research Development Analysis

NVAX Stock

USD 8.40 0.13 1.52%

Novavax financial indicator trend analysis is infinitely more than just investigating Novavax recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Novavax is a good investment. Please check the relationship between Novavax Gross Profit and its Research Development accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.

Gross Profit vs Research Development

Gross Profit vs Research Development Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Novavax Gross Profit account and Research Development. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Novavax's Gross Profit and Research Development is 0.94. Overlapping area represents the amount of variation of Gross Profit that can explain the historical movement of Research Development in the same time period over historical financial statements of Novavax, assuming nothing else is changed. The correlation between historical values of Novavax's Gross Profit and Research Development is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Gross Profit of Novavax are associated (or correlated) with its Research Development. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Research Development has no effect on the direction of Gross Profit i.e., Novavax's Gross Profit and Research Development go up and down completely randomly.

Correlation Coefficient

0.94

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Gross Profit

Gross profit is a required income statement account that reflects total revenue of Novavax minus its cost of goods sold. It is profit before Novavax operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Research Development

Most indicators from Novavax's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Novavax current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Novavax. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Novavax Stock please use our How to Invest in Novavax guide.At this time, Novavax's Selling General Administrative is fairly stable compared to the past year. Issuance Of Capital Stock is likely to rise to about 442.5 M in 2025, despite the fact that Tax Provision is likely to grow to (1.6 M).

Novavax fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Net Receivables	Non Current Liabilities Total	Intangible Assets	Short Long Term Debt Total	Common Stock Total Equity	Short Term Debt	Common Stock	Long Term Debt
Total Assets		0.81	0.95	-0.61	0.87	-0.85	-0.93	0.94	0.93	0.89	0.81	0.93	0.92	0.81	0.93	0.97	0.86	0.99	0.9	0.8	-0.48	0.56	-0.44	0.53	-0.35	0.32
Other Current Liab	0.81		0.91	-0.9	0.93	-0.63	-0.91	0.93	0.7	0.91	0.87	0.66	0.89	0.53	0.89	0.92	0.94	0.73	0.65	0.76	-0.38	0.35	-0.36	0.17	-0.24	0.03
Total Current Liabilities	0.95	0.91		-0.78	0.87	-0.86	-0.93	0.97	0.93	0.88	0.82	0.9	0.89	0.64	0.9	0.98	0.87	0.93	0.8	0.73	-0.43	0.53	-0.44	0.41	-0.35	0.21
Total Stockholder Equity	-0.61	-0.9	-0.78		-0.76	0.42	0.81	-0.76	-0.55	-0.74	-0.77	-0.48	-0.73	-0.31	-0.73	-0.79	-0.77	-0.53	-0.49	-0.67	0.37	-0.44	0.27	0.04	0.15	-0.2
Property Plant And Equipment Net	0.87	0.93	0.87	-0.76		-0.58	-0.94	0.92	0.67	1.0	0.95	0.66	0.98	0.75	0.97	0.93	1.0	0.78	0.79	0.91	-0.44	0.35	-0.39	0.24	-0.26	0.14
Net Debt	-0.85	-0.63	-0.86	0.42	-0.58		0.68	-0.79	-0.93	-0.6	-0.53	-0.94	-0.63	-0.5	-0.64	-0.78	-0.58	-0.89	-0.72	-0.39	0.24	-0.38	0.49	-0.55	0.46	-0.04
Retained Earnings	-0.93	-0.91	-0.93	0.81	-0.94	0.68		-0.94	-0.81	-0.95	-0.89	-0.78	-0.96	-0.76	-0.97	-0.97	-0.94	-0.87	-0.81	-0.89	0.51	-0.58	0.39	-0.35	0.26	-0.35
Accounts Payable	0.94	0.93	0.97	-0.76	0.92	-0.79	-0.94		0.87	0.91	0.81	0.86	0.91	0.72	0.93	0.96	0.91	0.9	0.74	0.76	-0.44	0.52	-0.43	0.49	-0.34	0.17
Cash	0.93	0.7	0.93	-0.55	0.67	-0.93	-0.81	0.87		0.7	0.59	0.99	0.74	0.65	0.76	0.88	0.66	0.97	0.76	0.57	-0.42	0.66	-0.42	0.64	-0.39	0.34
Non Current Assets Total	0.89	0.91	0.88	-0.74	1.0	-0.6	-0.95	0.91	0.7		0.96	0.68	0.99	0.77	0.99	0.94	1.0	0.81	0.83	0.93	-0.45	0.36	-0.38	0.25	-0.25	0.18
Non Currrent Assets Other	0.81	0.87	0.82	-0.77	0.95	-0.53	-0.89	0.81	0.59	0.96		0.57	0.95	0.64	0.93	0.89	0.95	0.72	0.86	0.91	-0.41	0.24	-0.38	0.0	-0.25	0.14
Cash And Short Term Investments	0.93	0.66	0.9	-0.48	0.66	-0.94	-0.78	0.86	0.99	0.68	0.57		0.72	0.68	0.75	0.86	0.64	0.97	0.76	0.55	-0.42	0.64	-0.41	0.68	-0.38	0.32
Common Stock Shares Outstanding	0.92	0.89	0.89	-0.73	0.98	-0.63	-0.96	0.91	0.74	0.99	0.95	0.72		0.81	1.0	0.95	0.98	0.85	0.87	0.94	-0.49	0.43	-0.42	0.29	-0.3	0.26
Other Current Assets	0.81	0.53	0.64	-0.31	0.75	-0.5	-0.76	0.72	0.65	0.77	0.64	0.68	0.81		0.82	0.73	0.73	0.78	0.74	0.82	-0.52	0.54	-0.39	0.64	-0.32	0.47
Other Stockholder Equity	0.93	0.89	0.9	-0.73	0.97	-0.64	-0.97	0.93	0.76	0.99	0.93	0.75	1.0	0.82		0.96	0.97	0.87	0.85	0.94	-0.5	0.48	-0.38	0.33	-0.26	0.3
Total Liab	0.97	0.92	0.98	-0.79	0.93	-0.78	-0.97	0.96	0.88	0.94	0.89	0.86	0.95	0.73	0.96		0.93	0.93	0.85	0.85	-0.49	0.55	-0.42	0.38	-0.32	0.3
Property Plant And Equipment Gross	0.86	0.94	0.87	-0.77	1.0	-0.58	-0.94	0.91	0.66	1.0	0.95	0.64	0.98	0.73	0.97	0.93		0.78	0.79	0.91	-0.43	0.33	-0.39	0.21	-0.25	0.13
Total Current Assets	0.99	0.73	0.93	-0.53	0.78	-0.89	-0.87	0.9	0.97	0.81	0.72	0.97	0.85	0.78	0.87	0.93	0.78		0.88	0.72	-0.47	0.6	-0.44	0.6	-0.37	0.35
Net Receivables	0.9	0.65	0.8	-0.49	0.79	-0.72	-0.81	0.74	0.76	0.83	0.86	0.76	0.87	0.74	0.85	0.85	0.79	0.88		0.82	-0.4	0.34	-0.48	0.26	-0.4	0.29
Non Current Liabilities Total	0.8	0.76	0.73	-0.67	0.91	-0.39	-0.89	0.76	0.57	0.93	0.91	0.55	0.94	0.82	0.94	0.85	0.91	0.72	0.82		-0.54	0.47	-0.29	0.18	-0.17	0.45
Intangible Assets	-0.48	-0.38	-0.43	0.37	-0.44	0.24	0.51	-0.44	-0.42	-0.45	-0.41	-0.42	-0.49	-0.52	-0.5	-0.49	-0.43	-0.47	-0.4	-0.54		-0.55	0.13	-0.27	0.08	-0.54
Short Long Term Debt Total	0.56	0.35	0.53	-0.44	0.35	-0.38	-0.58	0.52	0.66	0.36	0.24	0.64	0.43	0.54	0.48	0.55	0.33	0.6	0.34	0.47	-0.55		-0.06	0.63	-0.03	0.86
Common Stock Total Equity	-0.44	-0.36	-0.44	0.27	-0.39	0.49	0.39	-0.43	-0.42	-0.38	-0.38	-0.41	-0.42	-0.39	-0.38	-0.42	-0.39	-0.44	-0.48	-0.29	0.13	-0.06		-0.29	0.98	0.08
Short Term Debt	0.53	0.17	0.41	0.04	0.24	-0.55	-0.35	0.49	0.64	0.25	0.0	0.68	0.29	0.64	0.33	0.38	0.21	0.6	0.26	0.18	-0.27	0.63	-0.29		-0.32	0.36
Common Stock	-0.35	-0.24	-0.35	0.15	-0.26	0.46	0.26	-0.34	-0.39	-0.25	-0.25	-0.38	-0.3	-0.32	-0.26	-0.32	-0.25	-0.37	-0.4	-0.17	0.08	-0.03	0.98	-0.32		0.09
Long Term Debt	0.32	0.03	0.21	-0.2	0.14	-0.04	-0.35	0.17	0.34	0.18	0.14	0.32	0.26	0.47	0.3	0.3	0.13	0.35	0.29	0.45	-0.54	0.86	0.08	0.36	0.09

Click cells to compare fundamentals

Novavax Account Relationship Matchups

Novavax fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	1.6B	2.6B	2.3B	1.8B	2.1B	2.2B
Other Current Liab	(327.6M)	709.8M	1.5B	1.3B	1.4B	1.5B
Total Current Liabilities	322.0M	2.4B	2.5B	1.6B	1.9B	2.0B
Total Stockholder Equity	627.2M	(351.7M)	(634.1M)	(716.9M)	(645.2M)	(613.0M)
Property Plant And Equipment Net	180.0M	228.7M	400.5M	491.0M	564.6M	592.9M
Net Debt	(231.4M)	(1.1B)	(787.1M)	(339.4M)	(305.5M)	(290.2M)
Retained Earnings	(1.9B)	(3.6B)	(4.3B)	(4.8B)	(4.3B)	(4.1B)
Accounts Payable	54.3M	127.1M	216.5M	132.6M	152.5M	160.1M
Cash	553.4M	1.5B	1.3B	568.5M	653.8M	686.5M
Non Current Assets Total	334.3M	421.6M	555.3M	711.5M	818.2M	859.1M
Non Currrent Assets Other	13.2M	56.7M	28.5M	88.1M	101.3M	106.4M
Cash And Short Term Investments	711.0M	1.5B	1.3B	568.5M	653.8M	686.5M
Common Stock Shares Outstanding	57.6M	74.4M	78.2M	100.8M	115.9M	121.7M
Liabilities And Stockholders Equity	1.6B	2.6B	2.3B	1.8B	2.1B	2.2B
Other Current Assets	441.8M	176.1M	247.5M	236.4M	271.9M	285.5M
Other Stockholder Equity	2.5B	3.3B	3.6B	4.1B	4.7B	5.0B
Total Liab	955.3M	2.9B	2.9B	2.5B	2.9B	3.0B
Property Plant And Equipment Gross	180.0M	258.6M	447.8M	566.0M	650.9M	683.4M
Total Current Assets	1.2B	2.2B	1.7B	1.1B	1.3B	1.4B
Accumulated Other Comprehensive Income	7.0M	(1.4M)	(6.4M)	2.7M	2.4M	2.6M
Net Receivables	262.0M	455.0M	82.4M	297.2M	341.8M	358.9M
Non Current Liabilities Total	633.2M	538.1M	432.8M	937.1M	1.1B	1.1B
Intangible Assets	6.5M	5.6M	5.7M	4.8M	4.3M	4.1M
Short Long Term Debt Total	322.0M	454.0M	549.8M	229.1M	263.4M	140.8M
Common Stock Total Equity	3.8M	324K	714K	764K	878.6K	1.3M
Short Term Debt	322.0M	130.5M	352.1M	5.1M	5.9M	5.6M
Common Stock	714K	764K	868K	1.4M	1.6M	1.3M
Long Term Debt	322.0M	323.5M	166.5M	168.0M	193.2M	114.6M
Inventory	(166.7M)	(2.0B)	36.7M	41.7M	37.5M	39.4M
Property Plant Equipment	11.4M	180.0M	228.7M	400.5M	460.6M	483.6M
Other Liab	2.6M	3.4M	175.5M	185.0M	212.8M	223.4M
Current Deferred Revenue	273.2M	1.4B	370.1M	241.3M	277.5M	140.2M
Other Assets	5.4M	16.6M	28.5M	(57.9M)	(52.1M)	(49.5M)
Good Will	135.4M	131.5M	126.3M	127.5M	146.6M	153.9M
Short Term Investments	22.0M	0.0	157.6M	10.4M	12.0M	11.4M
Net Tangible Assets	(242.8M)	486.1M	(487.9M)	(760.4M)	(684.4M)	(650.1M)
Retained Earnings Total Equity	(1.3B)	(1.4B)	(1.9B)	(3.6B)	(3.3B)	(3.1B)
Long Term Debt Total	319.2M	320.6M	322.0M	323.5M	372.0M	234.9M
Capital Surpluse	1.1B	1.3B	2.5B	3.4B	3.9B	4.0B

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

Additional Tools for Novavax Stock Analysis

When running Novavax's price analysis, check to measure Novavax's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novavax is operating at the current time. Most of Novavax's value examination focuses on studying past and present price action to predict the probability of Novavax's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novavax's price. Additionally, you may evaluate how the addition of Novavax to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Novavax Gross Profit vs Research Development Analysis

Gross Profit vs Research Development

Gross Profit vs Research Development Correlation Analysis

Correlation Coefficient

Gross Profit

Research Development

Novavax fundamental ratios Correlations

Novavax Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Novavax fundamental ratios Accounts

Also Currently Popular

Additional Tools for Novavax Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Property Plant And Equipment Gross	+ 1.0	Non Current Assets Total
Other Stockholder Equity	+ 1.0	Common Stock Shares Outstanding
Total Current Assets	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Cash

Total Liab	- 0.97	Retained Earnings
Other Stockholder Equity	- 0.97	Retained Earnings
Common Stock Shares Outstanding	- 0.96	Retained Earnings
Non Current Assets Total	- 0.95	Retained Earnings
Property Plant And Equipment Gross	- 0.94	Retained Earnings
Accounts Payable	- 0.94	Retained Earnings